Plain-English translation of NCT06067438 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can prevent a dangerous heart rhythm problem called atrial fibrillation that sometimes happens after esophageal cancer surgery. After your surgery, you would either receive the medication or a placebo (a dummy treatment) for one week, and then researchers would track your heart rhythm and overall recovery for two months.
Many patients who undergo minimally invasive esophageal surgery develop an irregular heartbeat in the weeks after surgery, which can lead to longer hospital stays, serious complications, and sometimes even death. Doctors want to know if giving this medication right after surgery can prevent this dangerous heart problem from happening in the first place.
You likely qualify if…
You likely don't qualify if…
After your esophageal surgery, you will be randomly assigned to receive either the medication or a placebo. If you receive the medication, you'll get it through an IV for 4 days, then through a feeding tube for 3 more days. All participants will be monitored for two months after leaving the hospital, with follow-up visits and heart rhythm checks to see how well the treatment worked and to track any complications.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States